市場調査レポート

商品コード

1316960

心血管治療薬市場：薬剤タイプ、適応疾患、投与経路、購入形態、エンドユーザー別-2023-2030年の世界予測

Cardiovascular Drugs Market by Drug Type, Disease Indication, Route of Administration, Mode of Purchase, End-Users - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日: 2023年06月12日 | 発行: 360iResearch

| ページ情報: 英文 188 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF, Excel & Online Access - 1 Year (Single User License)

USD 4,749 744,453円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Up to 5 User License)

USD 5,749 901,213円

レポートPDF及びExcelを5名まで共有ご利用頂けるライセンスです。ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Site License)

USD 6,749 1,057,973円

レポートPDF及びExcelを同一事業所（所在地）内のすべての方でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Enterprise User License)

USD 8,749 1,371,493円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

心血管治療薬の世界市場は、2023年にCAGR 9.13%で826億5,000万米ドル、2030年には1,526億1,000万米ドルに達すると予測され、大きな成長が見込まれています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の心血管治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.心血管治療薬の世界市場規模および予測は？

2.予測期間中、世界の心血管治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.心血管治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.心血管治療薬の世界市場における競争戦略は？

5.心血管治療薬の世界市場における技術動向と規制の枠組みは？

6.心血管治療薬の世界市場における主要ベンダーの市場シェアは？

7.心血管治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

市場力学
- 促進要因
  - 心血管疾患の有病率の上昇
  - 医薬品開発のための研究開発投資の増加
  - 心血管疾患の予防と管理に対する政府の取り組み
- 抑制要因
  - 心血管治療薬の製品リコールと高コスト
- 機会
  - 心血管治療薬の有利な払い戻しポリシーとプログラム
  - 心血管疾患治療のための新規薬剤のイントロダクション
- 課題
  - 効率的で安全な医薬品開発における複雑さ
市場動向
COVID-19の累積的な影響
ロシア・ウクライナ紛争の累積的影響
高インフレの累積的影響
ポーターのファイブフォース分析
バリューチェーンとクリティカルパス分析
規制の枠組み
顧客のカスタマイズ

第6章心血管治療薬市場薬剤の種類別

アンジオテンシン阻害剤
抗凝固剤
高脂血症治療薬
降圧剤
抗血小板薬

第7章心血管治療薬市場：疾患適応症別

不整脈
冠動脈疾患
高脂血症
高血圧

第8章心血管治療薬市場：投与経路別

静脈内
オーラル
皮下

第9章心血管治療薬市場購入方法別

市販薬
処方箋ベースの医薬品

第10章心血管治療薬市場：エンドユーザー別

病院薬局
オンライン薬局
小売薬局

第11章南北アメリカの心血管治療薬市場

アルゼンチン
ブラジル
カナダ
メキシコ
米国

第12章アジア太平洋地域の心血管治療薬市場

オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第13章欧州・中東・アフリカの心血管治療薬市場

デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第14章競合情勢

FPNVポジショニングマトリクス
市場シェア分析：主要企業別
競合シナリオ分析：主要企業別

第15章掲載企業一覧

第16章付録

ディスカッションガイド
ライセンスと価格について

図表

LIST OF FIGURES

FIGURE 1. CARDIOVASCULAR DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CARDIOVASCULAR DRUGS MARKET SIZE, 2022 VS 2030
FIGURE 3. CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
FIGURE 5. CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2030 (%)
FIGURE 6. CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
FIGURE 7. CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2022 VS 2030 (%)
FIGURE 8. CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2022 VS 2030 (%)
FIGURE 9. CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 10. CARDIOVASCULAR DRUGS MARKET DYNAMICS
FIGURE 11. CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 12. CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 20. CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 21. CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

TABLE 1. CARDIOVASCULAR DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 5. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANGIOTENSIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 6. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERLIPIDEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 11. CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. CARDIOVASCULAR DRUGS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERLIPIDAEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 16. CARDIOVASCULAR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. CARDIOVASCULAR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. CARDIOVASCULAR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 20. CARDIOVASCULAR DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. CARDIOVASCULAR DRUGS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 23. CARDIOVASCULAR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. CARDIOVASCULAR DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. CARDIOVASCULAR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 42. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 44. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 46. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 47. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 48. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 49. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 69. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 70. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 71. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 73. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 74. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 75. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 76. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 78. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 84. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 85. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 86. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 88. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 114. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 115. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 116. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 118. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 130. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 131. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 132. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 134. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 135. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 136. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 137. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 139. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 140. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 141. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 142. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 144. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 145. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 146. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 147. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 149. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 150. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 151. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 152. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 154. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 160. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 161. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 162. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 164. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 175. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 177. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 179. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 180. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 181. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 182. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 184. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 185. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 186. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 187. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 189. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 205. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 206. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 207. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 209. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 220. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 221. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 222. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 224. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 235. CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 236. CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 237. CARDIOVASCULAR DRUGS MARKET LICENSE & PRICING

Product Code: MRR-434CCDA0519A

The Global Cardiovascular Drugs Market is forecasted to grow significantly, with a projected USD 82.65 billion in 2023 at a CAGR of 9.13% and expected to reach a staggering USD 152.61 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cardiovascular Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cardiovascular Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Type, market is studied across Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic, Antihypertensive, and Antiplatelet Drugs. The Anticoagulants commanded largest market share of 32.12% in 2022, followed by Antihypertensive.

Based on Disease Indication, market is studied across Arrhythmia, Coronary Artery Disease, Hyperlipidaemia, and Hypertension. The Coronary Artery Disease commanded largest market share of 34.23% in 2022, followed by Hyperlipidaemia.

Based on Route of Administration, market is studied across Intravenous, Oral, and Subcutaneous. The Oral commanded largest market share of 57.23% in 2022, followed by Intravenous.

Based on Mode of Purchase, market is studied across Over-The-Counter Drugs and Prescription-Based Drugs. The Prescription-Based Drugs commanded largest market share of 82.12% in 2022, followed by Over-The-Counter Drugs.

Based on End-Users, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Retail Pharmacies commanded largest market share of 67.32% in 2022, followed by Hospital Pharmacies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 37.00% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cardiovascular Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cardiovascular Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cardiovascular Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cardiovascular Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Cardiovascular Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Cardiovascular Drugs Market?

6. What is the market share of the leading vendors in the Global Cardiovascular Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Cardiovascular Drugs Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Cardiovascular Drugs Market, by Drug Type, 2022 vs 2030
4.3. Cardiovascular Drugs Market, by Disease Indication, 2022 vs 2030
4.4. Cardiovascular Drugs Market, by Route of Administration, 2022 vs 2030
4.5. Cardiovascular Drugs Market, by Mode of Purchase, 2022 vs 2030
4.6. Cardiovascular Drugs Market, by End-Users, 2022 vs 2030
4.7. Cardiovascular Drugs Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising Prevalence of Cardiovascular Disorders
  - 5.1.1.2. Increasing R&D Investments for Drug Development
  - 5.1.1.3. Government Initiatives for Prevention & Control of Cardiovascular Diseases
- 5.1.2. Restraints
  - 5.1.2.1. Product Recalls and High Cost of Cardiovascular Drugs
- 5.1.3. Opportunities
  - 5.1.3.1. Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
  - 5.1.3.2. Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
- 5.1.4. Challenges
  - 5.1.4.1. Complexities in Efficient and Safe Drug Development
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Cardiovascular Drugs Market, by Drug Type

6.1. Introduction
6.2. Angiotensin Inhibitors
6.3. Anticoagulants
6.4. Antihyperlipidemic
6.5. Antihypertensive
6.6. Antiplatelet Drugs

7. Cardiovascular Drugs Market, by Disease Indication

7.1. Introduction
7.2. Arrhythmia
7.3. Coronary Artery Disease
7.4. Hyperlipidaemia
7.5. Hypertension

8. Cardiovascular Drugs Market, by Route of Administration

8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous

9. Cardiovascular Drugs Market, by Mode of Purchase

9.1. Introduction
9.2. Over-The-Counter Drugs
9.3. Prescription-Based Drugs

10. Cardiovascular Drugs Market, by End-Users

10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies

11. Americas Cardiovascular Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Cardiovascular Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Cardiovascular Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

心血管治療薬市場：薬剤タイプ、適応疾患、投与経路、購入形態、エンドユーザー別-2023-2030年の世界予測

Cardiovascular Drugs Market by Drug Type, Disease Indication, Route of Administration, Mode of Purchase, End-Users - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

FPNVポジショニング・マトリックス

市場シェア分析

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 心血管治療薬市場薬剤の種類別

第7章 心血管治療薬市場：疾患適応症別

第8章 心血管治療薬市場：投与経路別

第9章 心血管治療薬市場購入方法別

第10章 心血管治療薬市場：エンドユーザー別

第11章 南北アメリカの心血管治療薬市場

第12章 アジア太平洋地域の心血管治療薬市場

第13章 欧州・中東・アフリカの心血管治療薬市場

第14章 競合情勢

第15章 掲載企業一覧

第16章 付録